The nation of Zimbabwe has declined a major American healthcare agreement worth 367 million US dollars (272 million pounds) over five years over Washington's insistence on confidential biological samples.
This rejection became public following a internal memorandum dated December was disclosed, revealing that President Emmerson Mnangagwa believed the arrangement was "lopsided".
An official representative has since explained that the United States was seeking biological samples for scientific study and commercial gain while was not willing to share the resulting advantages from future treatments.
"We must now begin the difficult and regrettable process of ending our health assistance in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the United States had donated over $1.9bn in health funding to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has called for continued negotiations to find a deal agreeable to both sides so the nation's critical HIV programme can proceed.
Wider Background
Zimbabwe's decision comes after a comparable case in Kenya, where a court blocked a similar deal with the US following concerns were raised about the safety of Kenyans' health data.
After returning to the presidency last year, US President Donald Trump has drastically cut overseas assistance and shut down the US Agency for International Development (USAID).
USAID had overseen assistance for the US government, but Trump claimed its expenditure was "wasteful" and his administration was pursuing government-to-government deals to enhance openness and responsibility.
According to statements, 16 nations in Africa have to date agreed to these new health pacts, constituting more than $18.3bn in committed funds.
Details of the Rejected Agreement
This assistance for Zimbabwe was intended to supported "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this collaboration could have provided significant advantages for Zimbabwean communities, especially the 1.2 million currently on HIV treatment through American-funded programmes," the Ambassador said.
However, government spokesperson Nick Mangwana maintained the proposed deal was "unfair".
"The proposal required Zimbabwe to surrender its biological resources and data for a long time, without any equivalent assurance of access to any medical innovations – such as vaccines, diagnostics, or treatments – that could be developed from that shared data," his statement read.
"In essence, our nation would supply the basic resources for medical research with no certainty that the resulting innovations would be accessible to our people should a new health crisis arise."
Sovereignty and Global Health
Mangwana further said that the US's withdrawal from the global health body and its pursuit of bilateral deals were upending frameworks already established via the global organization.
The spokesperson gave as an example its Pandemic Benefit-Sharing system designed to manage future pandemics.
"This mechanism is designed to ensure that when a country provides its data, the benefits – such as vaccines and treatments – are distributed fairly, not monopolised solely by those with the resources to develop them."
The government's concerns regarding the US deal "must not be interpreted as anti-American sentiment," Mangwana stressed.
"We encourage further dialogue with our American counterparts on how subsequent collaboration might be arranged in a manner that respects the independence and dignity of each country."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it understood the government's concerns, but recommended that negotiations must proceed since much of the country's Aids initiatives relied on external financing.
"Where specific concerns exist, such as those involving data governance or implementation frameworks, these can often be resolved via technical clarification and negotiated safeguards," the group commented.
The situation highlights the ongoing challenges between accepting crucial foreign assistance and protecting a country's data in an increasingly data-driven world.